Glenmark settles litigation with Daiichi Sankyo & Genzyme for colesevelam hydrochloride
Glenmark Pharmaceuticals today announced the settlement of litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) tiled with the US Food and Drug Administration (FDA) for Colesevelam Hydrochloride, a drug used in treatment of type-2 diabetes.

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries.
The Centre for DNA Fingerprinting and Diagnostics (CDFD) is an autonomous organization funded by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India. CDFD receives funding also from other agencies on specific collaborative projects.

